Inhibition of human UDP-glucuronosyltransferase enzyme by ripretinib: Implications for drug-drug interactions

Release Time:2024-09-03  Hits:

Indexed by: Journal Papers

Document Code: 363750

Date of Publication: 2023-05-01

Journal: TOXICOLOGY AND APPLIED PHARMACOLOGY

Volume: 466

ISSN: 0041-008X

Key Words: ACID; ANDROSTERONE; GASTROINTESTINAL STROMAL TUMORS; HUMAN LIVER-MICROSOMES; N-GLUCURONIDATION; PHARMACOGENETICS; POLYMORPHISMS; PREDICTION; SUBSTRATE; UGT1A4

Prev One:Insights into efficacy and safety of dapagliflozin treatment for the management in older adults with type 2 diabetes: a systematic review and meta-analysis

Next One:Higher risk of hepatotoxicity associated with cabozantinib in cancer patients